BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11181158)

  • 1. T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus b19.
    Franssila R; Hokynar K; Hedman K
    J Infect Dis; 2001 Mar; 183(5):805-9. PubMed ID: 11181158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.
    Franssila R; Hedman K
    Vaccine; 2004 Sep; 22(27-28):3809-15. PubMed ID: 15315862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection.
    Lindner J; Barabas S; Saar K; Altmann D; Pfister A; Fleck M; Deml L; Modrow S
    J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):356-61. PubMed ID: 16316401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.
    Franssila R; Auramo J; Modrow S; Möbs M; Oker-Blom C; Käpylä P; Söderlund-Venermo M; Hedman K
    Clin Exp Immunol; 2005 Oct; 142(1):53-61. PubMed ID: 16178856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Th-cell immunity against human bocavirus and parvovirus B19: proliferation and cytokine responses are similar in magnitude but more closely interrelated with human bocavirus.
    Kumar A; Filippone C; Lahtinen A; Hedman L; Söderlund-Venermo M; Hedman K; Franssila R
    Scand J Immunol; 2011 Feb; 73(2):135-40. PubMed ID: 21198754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans.
    Norbeck O; Isa A; Pöhlmann C; Broliden K; Kasprowicz V; Bowness P; Klenerman P; Tolfvenstam T
    J Virol; 2005 Sep; 79(18):12117-21. PubMed ID: 16140790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay.
    Bostic JR; Brown KE; Young NS; Koenig S
    J Infect Dis; 1999 Mar; 179(3):619-26. PubMed ID: 9952368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection.
    Pfrepper KI; Enders M; Motz M
    J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):362-5. PubMed ID: 16316402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.
    Ballou WR; Reed JL; Noble W; Young NS; Koenig S
    J Infect Dis; 2003 Feb; 187(4):675-8. PubMed ID: 12599085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of parvovirus B19 NS1-specific antibodies by ELISA and western blotting employing recombinant NS1 protein as antigen.
    Heegaard ED; Rasksen CJ; Christensen J
    J Med Virol; 2002 Jul; 67(3):375-83. PubMed ID: 12116031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1.
    Corcoran A; Mahon BP; Doyle S
    J Infect Dis; 2004 May; 189(10):1873-80. PubMed ID: 15122524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of a parvovirus B19 vaccine candidate.
    Chandramouli S; Medina-Selby A; Coit D; Schaefer M; Spencer T; Brito LA; Zhang P; Otten G; Mandl CW; Mason PW; Dormitzer PR; Settembre EC
    Vaccine; 2013 Aug; 31(37):3872-8. PubMed ID: 23827313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis of parvovirus B19 infection in hematological patients with partial red cell aplasia of the bone marrow].
    Iaguzhinskaia OE; Pivnik AV; Fevraleva IS; Sudarikov AB; Lisovina IuS; Loginova IV; Shitareva IV
    Ter Arkh; 2001; 73(8):50-6. PubMed ID: 11599268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.
    Von Landenberg P; Lehmann HW; Knöll A; Dorsch S; Modrow S
    Arthritis Rheum; 2003 Jul; 48(7):1939-47. PubMed ID: 12847688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgE, CD8(+)CD60+ T cells and IFN-alpha in human immunity to parvovirus B19 in selective IgA deficiency.
    Bluth MH; Norowitz KB; Chice S; Shah VN; Nowakowski M; Durkin HG; Smith-Norowitz TA
    Hum Immunol; 2005 Oct; 66(10):1029-38. PubMed ID: 16386644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent parvovirus B19 infection detected by specific CD4+ T-cell responses in a patient with hepatitis and polyarthritis.
    Pongratz G; Lindner J; Modrow S; Schimanski S; Schölmerich J; Fleck M
    J Intern Med; 2009 Sep; 266(3):296-301. PubMed ID: 19549095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candidate recombinant vaccine for human B19 parvovirus.
    Bansal GP; Hatfield JA; Dunn FE; Kramer AA; Brady F; Riggin CH; Collett MS; Yoshimoto K; Kajigaya S; Young NS
    J Infect Dis; 1993 May; 167(5):1034-44. PubMed ID: 8486937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of functional B cell memory against parvovirus B19 capsid proteins may be associated with resolution of persistent infection.
    Corcoran A; Crowley B; Dewhurst C; Pizer BL; Doyle S
    J Med Virol; 2006 Jan; 78(1):125-8. PubMed ID: 16299723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-infection of human parvovirus B19 in Vietnamese patients with hepatitis B virus infection.
    Toan NL; Song le H; Kremsner PG; Duy DN; Binh VQ; Duechting A; Kaiser H; Torresi J; Kandolf R; Bock CT
    J Hepatol; 2006 Sep; 45(3):361-9. PubMed ID: 16684578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
    J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.